Janux Therapeutics, Inc. (JANX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$20.24+2.22%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · JANX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -8.6% |
| Our one-year growth estimate | diamond | -53.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 44.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
JANX — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…
Why it matters: Improving cash flow is critical for Janux's financial health. It shows the company is managing expenses better.
Supportive ifCash flow from operations will improve more in Q2 2026. It gets closer to breakeven.
Worry ifCash flow from operations worsens or remains negative in Q2 2026.
Why it matters: Starting the clinical trial for JANX013 is a key step in expanding Janux's pipeline. It shows progress in their cancer treatment efforts.
Supportive ifJANX013 enters clinical trials as planned in the second half of 2026.
Worry ifThe start of JANX013 is delayed or canceled.
Why it matters: This partnership may lead to big steps in Janux's drug development. Progress can improve market views.
Supportive ifThey share updates on the partnership. New milestones are also shared.
Worry ifNo updates or bad news about the partnership.
Why it matters: A significant drop in cash could signal trouble for funding ongoing projects. Maintaining cash is crucial for development.
Worry ifCash and cash equivalents remain stable or increase from $970.9 million in Q2 2026.
Less concerning ifCash and cash equivalents fall below $950 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$138 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $450 loss on $10,000 · 4.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,494 loss on $10,000 · 64.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Improving cash flow signals better financial health. It is crucial for long-term growth.
Supportive ifCash from operating activities improves to less than -$10M in the next quarter.
Worry ifCash from operating activities gets worse or stays above -$12.34M.
Why it matters: New data could enhance understanding of JANX007's effectiveness. It may attract more interest from investors and partners.
Supportive ifMore clinical data for JANX007 will be shown at a medical meeting in early 2027.
Worry ifNo new data is presented, or the data is not favorable.
Why it matters: Progress in this partnership is key for growth. It could lead to new therapies and revenue.
Supportive ifA press release or update confirms a milestone reached in the work with BMS.
Worry ifNo news or problems reported in the work with BMS.
Why it matters: This data will show how well JANX011 works in healthy volunteers. Positive results could boost confidence in Janux's pipeline.
Supportive ifInitial clinical data from the Phase 1 study of JANX011 is out as expected.
Worry ifNo data is released or results are disappointing.
Why it matters: More people are joining the study. This shows interest and possible success in treating mCRPC. It may affect future funding and partnerships.
Supportive ifEnrollment in the JANX007 Phase 1b trial continues to meet or exceed targets.
Worry ifEnrollment slows down a lot or does not meet expectations.
Why it matters: Maintaining a strong cash position is crucial for funding ongoing clinical trials and operations. A drop could raise concerns.
Watch forCash and cash equivalents remain stable around $970 million.
Also watch forCash position falls below $950 million.